Total Funding
79
51
Total FundingPost-IPO Equity raised
Growth Score
-10 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
114457
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company.
- Daren Ure: Chief Scientific Officer & Director of Research and Development
- Todd Hobbs: Chief Medical Officer
About the Company
Hepion Pharmaceuticals provides the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
The company is a biopharmaceutical business that specializes in the creation of medication therapies for the management of chronic liver illnesses.
Hepion
Pharmaceuticals was established in 2013.
